Hong-Ou-Mandel interference between independent III-V on silicon waveguide integrated lasers

The versatility of silicon photonic integrated circuits has led to a widespread usage of this platform for quantum information based applications, including Quantum Key Distribution (QKD). However, the integration of simple high repetition rate photon sources is yet to be achieved. The use of weak-coherent pulses (WCPs) could represent a viable solution. For example, Measurement Device Independent QKD (MDI-QKD) envisions the use of WCPs to distill a secret key immune to detector side channel attacks at large distances. Thus, the integration of III-V lasers on silicon waveguides is an interesting prospect for quantum photonics. Here, we report the experimental observation of Hong-Ou-Mandel interference with 46\pm 2% visibility between WCPs generated by two independent III-V on silicon waveguide integrated lasers. This quantum interference effect is at the heart of many applications, including MDI-QKD. Our work represents a substantial first step towards an implementation of MDI-QKD fully integrated in silicon, and could be beneficial for other applications such as standard QKD and novel quantum communication protocols.Comment: 5 pages, 3 figure

Bayesian Approach to Searching for Susceptibility Genes: Gc2 and EsD1 Alleles and Multiple Sclerosis

Multiple sclerosis (MS) is one of the most common causes of neurological disability in early adulthood. The current literature is interested in identifying biological or DNA markers associated with genetic susceptibility to MS. The aim of this study is to investigate, by means of Bayesian statistical inference, whether the presence of Gc2 (Gc = group-specific component) and/or EsD1 (EsD = esterase D) alleles affects MS susceptibility. Gc and EsD are two classical genetic markers, being the first a serum protein polymorphism, the latter an isoenzyme polymorphism. The interest of the proposed statistical approach of searching for MS susceptibility genes relies on the analysis of two different functions, one function being inferred from our results on 56 unrelated patients from central Italy affected by MS, the other one from Italian and worldwide epidemiological data. The graphical analysis suggests that MS susceptibility is influenced by both Gc2 and EsD1 alleles; and EsD1 allele is more informative than Gc2. These results point out the advantages of the Bayesian approach in searching for susceptibility genes. Furthermore, the significant association between the considered alleles and the susceptibility to MS suggests possible hypotheses about the pathogenesis of the disease

Shortest node-disjoint paths on random graphs

A localized method to distribute paths on random graphs is devised, aimed at finding the shortest paths between given source/destination pairs while avoiding path overlaps at nodes. We propose a method based on message-passing techniques to process global information and distribute paths optimally. Statistical properties such as scaling with system size and number of paths, average path-length and the transition to the frustrated regime are analyzed. The performance of the suggested algorithm is evaluated through a comparison against a greedy algorithm

Sutureless Valve in Repeated Aortic Valve Replacement: Results from an International Prospective Registry

Objective: To report early and midterm results registry of patients undergoing repeated aortic valve replacement (RAVR) with sutureless prostheses from an international prospective registry (SURE-AVR). Methods: Between March 2011 and June 2019, 69 patients underwent RAVR with self-expandable sutureless aortic bioprostheses at 22 international cardiac centers.Results: Overall mortality was 2.9% with a predicted logistic EuroSCORE 11 of 10.7%. Indications for RAVR were structural valve dysfunction (84.1%) and infective prosthetic endocarditis (15.9%) and were performed in patients with previously implanted bioprostheses (79.7%), mechanical valves (15.9%), and transcatheter valves (4.3%). Minimally invasive approach was performed in 15.9% of patients. Rate of stroke was 1.4% and rate of early valve-related reintervention was 1.4%. Overall survival rate at 1 and 5 years was 97% and 91%, respectively. No major paravalvular leak occurred. Rate of pacemaker implantation was 5.8% and 0.9% per patient-year early and at follow-up, respectively. The mean transvalvular gradient at 1-year and 5-year follow-up was 10.5 mmHg and 11.5 mmHg with a median effective orifice area of 1.8 cm 2 and 1.8 cm 2 , respectively. Conclusions: RAVR with sutureless valves is a safe and effective approach and provides excellent clinical and hemodynamic results up to 5 years

Roadmap on multimode photonics

Multimode devices and components have attracted considerable attention in the last years, and different research topics and themes have emerged very recently. The multimodality can be seen as an additional degree of freedom in designing devices, thus allowing for the development of more complex and sophisticated components. The propagation of different modes can be used to increase the fiber optic capacity, but also to introduce novel intermodal interactions, as well as allowing for complex manipulation of optical modes for a variety of applications. In this roadmap we would like to give to the readers a comprehensive overview of the most recent developments in the field, presenting contributions coming from different research topics, including optical fiber technologies, integrated optics, basic physics and telecommunications

Twice‐weekly ixazomib in combination with lenalidomide‐dexamethasone in patients with newly diagnosed multiple myeloma

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/144661/1/bjh15394.pdfhttps://deepblue.lib.umich.edu/bitstream/2027.42/144661/2/bjh15394_am.pd

Safety profile of a miniaturized insertable cardiac monitor: results from two prospective trials

BACKGROUND: Insertable cardiac monitors (ICM) are used to continuously monitor the patient's ECG. In response to patient activation or based on automated device algorithms, arrhythmia episodes are stored and automatically transmitted daily to the clinician. Thus, ICMs can be used to diagnose arrhythmias in at-risk patients and in those with symptoms potentially attributable to arrhythmias. The ICM described in the present report has undergone a dramatic change in size and method of insertion. METHODS: To evaluate the safety profile of the ICM procedure, we analyzed procedure-related adverse events from two separate trials: a controlled, non-randomized multicenter study (Reveal LINQ™ Usability study) and a multicenter registry (Reveal LINQ™ Registry) evaluating real-world experience. For the Registry we reported all procedure-related adverse events upon occurrence, whereas for the Usability study, we reported events occurring during the first month of follow-up. RESULTS: The Usability study enrolled 151 patients (age 56.6 ± 12.1 years; male 67%) at 16 centers; during follow-up, an infection was observed in 1.3% patients and a procedure-related serious adverse event (SAE) in 0.7% patients. The Registry enrolled 122 patients (age 61.0 ± 17.8 years; male 47%) at 7 centers; during follow-up, an infection was observed in 1.6% patients and a procedure-related SAE in 1.6% patients. CONCLUSIONS: The cumulative experience from a controlled clinical trial and a "real-world" registry, demonstrate that the new ICM can be inserted with very low incidence of adverse events.Suneet Mittal, Prashanthan Sanders, Evgeny Pokushalov, Lukas Dekker, Dean Kereiakes, Edward J. Schloss, Erika Pouliot, Noreli Franco, Yan Zhong, Marco Di Bacco and Helmut Pürerfellne

Minimal residual disease in Myeloma: Application for clinical care and new drug registration

The development of novel agents has transformed the treatment paradigm for multiple myeloma, with minimal residual disease (MRD) negativity now achievable across the entire disease spectrum. Bone marrow–based technologies to assess MRD, including approaches using next-generation flow and next-generation sequencing, have provided real-time clinical tools for the sensitive detection and monitoring of MRD in patients with multiple myeloma. Complementary liquid biopsy–based assays are now quickly progressing with some, such as mass spectrometry methods, being very close to clinical use, while others utilizing nucleic acid–based technologies are still developing and will prove important to further our understanding of the biology of MRD. On the regulatory front, multiple retrospective individual patient and clinical trial level meta-analyses have already shown and will continue to assess the potential of MRD as a surrogate for patient outcome. Given all this progress, it is not surprising that a number of clinicians are now considering using MRD to inform real-world clinical care of patients across the spectrum from smoldering myeloma to relapsed refractory multiple myeloma, with each disease setting presenting key challenges and questions that will need to be addressed through clinical trials. The pace of advances in targeted and immune therapies in multiple myeloma is unprecedented, and novel MRD-driven biomarker strategies are essential to accelerate innovative clinical trials leading to regulatory approval of novel treatments and continued improvement in patient outcomes